| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| ln Vitro |
W23-1006 (5 μM; 24 h) significantly increased mA abundance in MDA-MB-231 and BT549 cells [1]. W23-1006 (3.16–31.6 μM; 24 h) inhibited the viability of MDA-MB-231 and BT549 cells [1]. W23-1006 (5 μM) significantly reduced the invasion area of TNBC cells and inhibited cell migration [1]. W23-1006 (5–10 μM) induced apoptosis in MDA-MB-231 cells and reduced the proportion of cells in the G2/M phase [1].
|
|---|---|
| ln Vivo |
W23-1006 (25 mg/kg; intraperitoneal injection; once daily for 14 days) has an antitumor effect on breast cancer in vivo [1]. W23-1006 (25 mg/kg; intraperitoneal injection; once daily for 10 days) significantly inhibited lung metastasis of triple-negative breast cancer (TNBC) [1]. The half-life (t1/2) of W23-1006 (single dose 25 mg/kg; intraperitoneal injection) in mice ranged from 0.509 to 0.983 hours, and the peak plasma concentration (Cmax, range 1715-2108 ng/mL) was reached within 15 minutes [1]. Neither 100 mg/kg nor 250 mg/kg doses of W23-1006 (intraperitoneal injection) caused adverse reactions or death in KM mice (22-27 g) [1].
|
| Cell Assay |
RT-PCR[1]
Cell Types: MDA-MB-231 and BT549 cells Tested Concentrations: 5 μM Incubation Duration: 24 hours Experimental Results: mA abundance in cells increased significantly. Cell viability assay [1] Cell Types: MDA-MB-231 and BT549 cells Tested Concentrations: 3.16 μM, 10 μM, 31.62 μM Incubation Duration: 24 hours Experimental Results: The inhibitory effect on the viability of MDA-MB-231 and BT549 cells was 10.31 μM and 6.338 μM, respectively. |
| Animal Protocol |
Animal/Disease Models:MDA-MB-231 cells[1] were subcutaneously injected into immunodeficient female mice.
Doses: 25 mg/kg (5% DMSO, 10% Kolliphor HS 15, and 85% saline). Route of Administration: Intraperitoneal injection; once daily for 14 days. Experimental Results: Tumor volume and weight were significantly reduced. FN1 and Ki-67 protein expression levels were significantly decreased. Animal/Disease Models:Immunodeficient female mice were injected with MDA-MB-231LMF3 via the tail vein [1]. Doses: 25 mg/kg. Route of Administration: Intraperitoneal injection; once daily for 10 consecutive days. Experimental Results: Inhibited lung metastasis of triple-negative breast cancer. No obvious pathological abnormalities were observed in HE staining of multiple organs, including the heart, liver, spleen, lungs, and kidneys. There was no significant difference in the levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in mouse serum, and they had no effect on liver function. |
| References |
| Molecular Formula |
C17H12BRN3O5
|
|---|---|
| Molecular Weight |
418.20
|
| CAS # |
3035498-92-8
|
| Appearance |
Brown to reddish brown solid
|
| SMILES |
O=C(/C1=C\C2=CC([N+]([O-])=O)=CC(Br)=C2)NN(C3=CC=C(C=C3)OC)C1=O
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: 请将本产品存放在密封且受保护的环境中（例如氮气下），避免暴露在潮湿环境中。 |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~239.12 mM; with sonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.98 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you canAdd 100 μL of DMSO stock solution (25.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of physiological saline: Dissolve 0.9 g of sodium chloride in double-distilled water and dilute to 100 mL to obtain clear physiological saline. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3912 mL | 11.9560 mL | 23.9120 mL | |
| 5 mM | 0.4782 mL | 2.3912 mL | 4.7824 mL | |
| 10 mM | 0.2391 mL | 1.1956 mL | 2.3912 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
